<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25263437</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>9</Month>
            <Day>29</Day>
        </DateCreated>
        <DateRevised>
            <Year>2014</Year>
            <Month>9</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5594</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncogene</Title>
                <ISOAbbreviation>Oncogene</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/onc.2014.300</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Tissue inhibitor of metalloproteinases-1 (TIMP-1) recently emerged as a pro-metastatic factor highly associated with poor prognosis in a number of cancers. This correlation seemed paradox as TIMP-1 is best described as an inhibitor of pro-tumourigenic matrix metalloproteinases. Only recently, TIMP-1 has been revealed as a signalling molecule that can regulate cancer progression independent of its inhibitory properties. In the present study, we demonstrate that an increase of both exogenous and endogenous TIMP-1 led to the upregulation of miR-210 in a CD63/PI3K/AKT/HIF-1-dependent pathway in lung adenocarcinoma cells. TIMP-1 induced P110/P85 PI3K-signalling and AKT phosphorylation. It also led to increase of HIF-1慣 protein levels positively correlating with HIF-1-regulated mRNA expression and upregulation of the microRNA miR-210. Downstream targets of miR-210, namely FGFRL1, E2F3, VMP-1, RAD52 and SDHD, were decreased in the presence of TIMP-1. Upon the overexpression of TIMP-1 in tumour cells, miR-210 was accumulated in exosomes in vitro and in vivo. These exosomes promoted tube formation activity in human umbilical vein endothelial cell (HUVECs), which was reflected in increased angiogenesis in A549L-derived tumour xenografts. Activation and elevation of PI3K, AKT, HIF-1A and miR-210 in tumours additionally confirmed our in vitro data. This new pro-tumourigenic signalling function of TIMP-1 may explain why elevated TIMP-1 levels in lung cancer patients are highly correlated with poor prognosis.Oncogene advance online publication, 29 September 2014; doi:10.1038/onc.2014.300.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cui</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <Identifier Source="ORCID">0000000333588958</Identifier>
                    <Affiliation>Institut f체r Experimentelle Onkologie und Therapieforschung, Klinikum Rechts der Isar der Technischen Universit채t M체nchen, Ismaninger Stra?웕 22, Munich, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Seubert</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Institut f체r Experimentelle Onkologie und Therapieforschung, Klinikum Rechts der Isar der Technischen Universit채t M체nchen, Ismaninger Stra?웕 22, Munich, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Stahl</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Physik Department, Walter Schottky Institute, Technische Universit채t M체nchen, Am Coulombwall 4a, Munich, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dietz</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Physik Department, Walter Schottky Institute, Technische Universit채t M체nchen, Am Coulombwall 4a, Munich, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Reuning</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                    <Affiliation>Klinische Forschergruppe der Frauenklinik, Klinikum Rechts der Isar der Technischen Universit채t M체nchen, Ismaninger Stra?웕 22, Munich, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Moreno-Leon</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>1] University of Nice Sophia-Antipolis, Nice, France [2] Institut de Pharmacologie Mol챕culaire et Cellulaire, Centre National de la Recherche Scientifique, UMR 6097 CNRS/UNSA, Sophia Antipolis, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ilie</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>1] University of Nice Sophia-Antipolis, Nice, France [2] Laboratory of Clinical and Experimental Pathology and Hospital Integrated Biobank, Centre Hospitalier Universitaire de Nice, Nice, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hofman</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>1] University of Nice Sophia-Antipolis, Nice, France [2] Laboratory of Clinical and Experimental Pathology and Hospital Integrated Biobank, Centre Hospitalier Universitaire de Nice, Nice, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nagase</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Muscolosketal Sciences, University of Oxford, London, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mari</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>1] University of Nice Sophia-Antipolis, Nice, France [2] Institut de Pharmacologie Mol챕culaire et Cellulaire, Centre National de la Recherche Scientifique, UMR 6097 CNRS/UNSA, Sophia Antipolis, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kr체ger</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Institut f체r Experimentelle Onkologie und Therapieforschung, Klinikum Rechts der Isar der Technischen Universit채t M체nchen, Ismaninger Stra?웕 22, Munich, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Oncogene</MedlineTA>
            <NlmUniqueID>8711562</NlmUniqueID>
            <ISSNLinking>0950-9232</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">onc2014300</ArticleId>
            <ArticleId IdType="doi">10.1038/onc.2014.300</ArticleId>
            <ArticleId IdType="pubmed">25263437</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
